Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Table 2 Multivariable predictors for the development of new or worsened hypertension (HTN) (n = 280)

Variable	Hazard ratio	95% Confidence interval	p value
Age*	1.02	(1.00 – 1.04)	0.078
Sex: Female vs. Male	0.59	(0.37 – 0.92)	0.021
Black/African-American	4.35	(1.21 – 15.63)	0.024
BMI*	1.05	(1.01 – 1.08)	0.005
Smoking status: Current/Previous vs. Never	0.71	(0.50 – 1.01)	0.057
Prior DM	1.38	(0.71 – 2.69)	0.339
Prior CKD	0.58	(0.12 – 2.77)	0.496
Prior AF/AFlutter	1.63	(1.06 – 2.49)	0.025
Hematologic diagnosis
CLL	Reference	Reference
MCL	1.15	(0.34 – 3.96)	0.82
Other^‡	0.22	(0.07 – 0.65)	0.006
Number of prior anticancer therapies	0.87	(0.78 – 0.97)	0.015
Baseline SBP by baseline HTN status interaction	0.99	(0.98 – 0.99)	0.001†

Bold indicates statistical significance, using the significance level α = 0.05
AF atrial fibrillation, Aflutter atrial flutter, BMI body mass index, CKD chronic kidney disease, DM diabetes mellitus, SBP systolic blood pressure. *Considered a continuous variable. †Omnibus p value (reflects overall variable effect). ‡Diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, graft-versus-host disease, marginal zone lymphoma, and Waldenström’s macroglobulinemia.

ISSN: 1756-8722